Clinical Trials on Chronic Obstructive Pulmonary Disease COPD in Russian Federation

Total 1015 results

Chiesi Farmaceutici S.p.A.

Completed

Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD (CARSAF)

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
Meshalkin Research Institute of Pathology of Circulation

Unknown

Chronic Obstructive Pulmonary Disease as a Predictor of Mortality in Cardiac Surgery

Chronic Obstructive Pulmonary Disease | Cardiac Surgery

Russian Federation
AstraZeneca

Completed

Aclidinium/Formoterol Fixed Combination Dose Finding Study

Chronic Obstructive Pulmonary Disease (COPD)

Russian Federation, Australia, Czech Republic, Poland
AstraZeneca

Recruiting

MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiA (MINERVA)

Chronic Obstructive Pulmonary Disease

Russian Federation
Université Catholique de Louvain
Northern State Medical University

Completed

A RESearch on the PrEvalence and the Diagnosis of COPD and Its Tobacco-related Etiology (RESPECT)

Chronic Obstructive Pulmonary Disease

Russian Federation
Novosibirsk City Hospital #2
Siberian Branch of the Russian Academy of Medical Sciences

Completed

Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures 2

Chronic Obstructive Pulmonary Disease

Russian Federation
Novosibirsk City Hospital #2
Siberian Branch of the Russian Academy of Medical Sciences

Completed

Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures

Chronic Obstructive Pulmonary Disease

Russian Federation
AstraZeneca

Completed

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)

Chronic Obstructive Pulmonary Disease | COPD

Austria, France, Hungary, Italy, Poland, Portugal, Russian Federation, South Africa, Spain, Canada, United Kingdom, Australia, Netherlands, Switzerland
I.M. Sechenov First Moscow State Medical University

Unknown

Energy Supply in Athletes and Untrained Persons With Bronchopulmonary Diseases

Chronic Obstructive Pulmonary Disease | Bronchitis | Acute Respiratory Infection | Community-acquired Pneumonia

Russian Federation
Interregional Public Organization, Russian Respiratory...

Unknown

Registry of COPD Patients From Outpatient Polyclinic Healthcare Institutions of the Russian Federation in Moscow

Pulmonary Disease, Chronic Obstructive

Russian Federation
Ryazan State Medical University

Completed

Chronic Obstructive Pulmonary Disease in Combination With Atherosclerosis (Clinical and Biochemical Study)

Chronic Obstructive Pulmonary Disease | Peripheral Artery Disease

Russian Federation
Mereo BioPharma
Novartis

Completed

Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation

Chronic Obstructive Pulmonary Disease

Russian Federation, Bulgaria, Romania
AstraZeneca

Completed

Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol

Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, France, Italy, Poland, Russian Federation, Ukraine, Hungary, Slovakia
Mikhael Petrovich Kostinov
Pfizer

Completed

Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology

Chronic Obstructive Pulmonary Disease | Pneumococcal Infections | Asthma

Russian Federation
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Russian Federation
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Czech Republic, France, Hungary, Italy, Peru, Poland, Russian Federation, South Africa, Spain, Ukraine
Eurasian Association of Therapists

Recruiting

Real Clinical Practice Register of AlbUminuRia Detection in Patients With Previously undiAgnosed Chronic Kidney Disease (AURA)

COVID-19 | Hypertension | Cancer | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Atrial Fibrillation | PreDiabetes | Ischemic Heart Disease | Chronic Heart Failure | Urolithiasis

Russian Federation
AstraZeneca

Completed

Exacerbations and Their Outcomes International (EXACOS International) (EXACOS-Intl)

Chronic Obstructive Pulmonary Disease

Taiwan, Russian Federation, Mexico, Chile
AstraZeneca
Parexel International Ltd; Cognizant Technology Solution; Center for Information... and other collaborators

Completed

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (AERISTO)

Chronic Obstructive Pulmonary Disease COPD

United States, Canada, France, Russian Federation, Ukraine, Hungary, Bulgaria
Sunovion Respiratory Development Inc.

Completed

A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-5)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Czechia, Hungary, Russian Federation
Novartis Pharmaceuticals

Completed

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

Colombia, India, Korea, Republic of, Poland, Croatia, Estonia, Hungary, United Kingdom, Israel, Latvia, Turkey, Argentina, Panama, Mexico, Russian Federation, Serbia, Slovenia
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Russian Federation, Germany, Denmark, Italy, Canada, Czech Republic, Hungary, India, Slovakia, France, Colombia, Finland, Taiwan, Iceland, Peru
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (GLOW6)

Chronic Obstructive Pulmonary Disease (COPD)

Greece, Belgium, Bulgaria, Turkey, Hungary, Slovakia, Spain, United Kingdom, Russian Federation, Ireland
Federal Research Clinical Center of Federal Medical...

Withdrawn

Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema

Pulmonary Emphysema

Russian Federation
AstraZeneca

Completed

Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement (CLOUD)

COPD

Russian Federation
AstraZeneca

Completed

Non-interventional Study of Spirometry Use to Diagnose COPD (Chronic Obstructive Pulmonary Disease) and to Prescribe Treatment to COPD Patients in the Outpatient Institutions (SUPPORT)

COPD

Russian Federation
AstraZeneca

Completed

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

Chronic Obstructive Pulmonary Disease (COPD)

France, Germany, United Kingdom, United States, Australia, Austria, Brazil, Hungary, New Zealand, Romania, Russian Federation
Boehringer Ingelheim

Completed

OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)

Pulmonary Disease, Chronic Obstructive

Austria, Czechia, Hungary, Israel, Romania, Russian Federation, Slovakia, Slovenia, Switzerland
AstraZeneca

Completed

Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination

Chronic Obstructive Pulmonary Disease (COPD)

Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Sweden, Ukraine, United Kingdom
Novartis Pharmaceuticals

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (SHINE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan
AstraZeneca

Completed

A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Andorra, Austria, Belgium, Bulgaria, Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Romania, Russian Federation, Spain, United Kingdom
AstraZeneca

Recruiting

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. (TITANIA)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, Germany, United Kingdom, China, Philippines, Italy, Chile, Taiwan, Thailand, France, Puerto Rico, Israel, Peru, Colombia, Poland, Brazil, Russian Federation, Romania, Greece
Novartis Pharmaceuticals

Completed

QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Colombia, India, Korea, Republic of, Poland, Romania, South Africa, Italy, Austria, Belgium, Croatia, Estonia, Hungary, Russian Federation, Taiwan, Turkey, Japan, Spain, Sweden, United Kingdom, China, Thailand, Canada, Hong Kong and more
GlaxoSmithKline

Completed

An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Romania, Russian Federation, Belgium, Denmark, Netherlands
Mundipharma Research Limited

Completed

A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD

Chronic Obstructive Pulmonary Disease

Ukraine, United Kingdom, Spain, Bulgaria, South Africa, Russian Federation, Germany, Hungary, Lithuania, Slovakia, Macedonia, The Former Yugoslav Republic of, Latvia, Romania, Korea, Republic of, Poland
GlaxoSmithKline

Completed

Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Finland, Russian Federation, United Kingdom
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease Endpoints Study

Pulmonary Disease, Chronic Obstructive

Russian Federation, United States, Estonia, Chile
AstraZeneca

Completed

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

Lung Diseases | Pulmonary Disease | COPD | COPD Exacerbation | Respiratory Disorders | Chronic Obstructive Airway Disease | Chronic Obstructive Lung Diseases

United States, Argentina, Canada, Chile, Colombia, Italy, Malaysia, Mexico, Peru, Philippines, Romania, Russian Federation, Serbia, Spain, Taiwan, Thailand, Ukraine
Adams Respiratory Therapeutics

Completed

Phase 2 Study - Erdosteine in Patients With CB/COPD

Chronic Obstructive Pulmonary Disease | Chronic Bronchitis

United States
GlaxoSmithKline

Completed

Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Russian Federation, Sweden, United Kingdom
GlaxoSmithKline

Completed

Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients

Pulmonary Disease, Chronic Obstructive

Russian Federation, Estonia, Finland, Germany, Netherlands, Slovakia
AstraZeneca

Completed

Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU (OCEAN)

Chronic Obstructive Pulmonary Disease

Bulgaria, Russian Federation, Romania, Ukraine, Japan
Pfizer

Completed

A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease

Australia, Netherlands, Canada, Korea, Republic of, Argentina, Hungary, South Africa, France, Russian Federation, Chile, Czechia, Greece, United Kingdom
Zuzana Zbožínková, M.Sc.
Boehringer Ingelheim

Completed

Phenotypes of COPD in Central and Eastern Europe (POPE)

Chronic Obstructive Pulmonary Disease

Latvia, Croatia, Austria, Bulgaria, Czech Republic, Hungary, Poland, Russian Federation, Serbia, Slovakia, Slovenia
Novosibirsk Scientific Research Institute for Circulatory...

Unknown

Interventional Treatment of Residual Pulmonary Hypertension in Patients After Pulmonary Thromboendarterectomy

Chronic Thromboembolic Pulmonary Hypertension

Russian Federation
Novosibirsk Scientific Research Institute for Circulatory...

Unknown

Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region (NCTEPHR)

Chronic Thromboembolic Pulmonary Hypertension

Russian Federation
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

Pulmonary Disease, Chronic Obstructive

Austria, Belgium, Canada, Germany, Russian Federation
Janssen Research & Development, LLC

Completed

An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United Kingdom, United States, Belgium, Germany, Romania, Canada, Netherlands, Russian Federation, Poland, Hungary, Czechia
GlaxoSmithKline

Completed

Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients

Pulmonary Disease, Chronic Obstructive

Germany, Sweden, New Zealand, Russian Federation, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Ukraine, Argentina, Chile, Poland, Russian Federation, Turkey, United States, Australia, Canada, Germany

Clinical Trials on Chronic Obstructive Pulmonary Disease COPD in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations